<DOC>
	<DOCNO>NCT00609362</DOCNO>
	<brief_summary>Osteoporosis generalise bone disease lead increase risk fracture . The disease cause partly environmental partly genetic factor . It well know fat content bone marrow increase osteoporotic patient . Animal study suggest stimulation bone marrow stem cell molecule PPARgamma drug rosiglitazone convert stem cell fat cell instead bone cell thereby decrease bone strength . In single study healthy volunteer treat rosiglitazone 14 week decrease bone mineral density . In present study wish investigate effect treatment bone fat tissue . 25 woman age 60 treat rosiglitazone 8 mg/day 14 week compare 25 woman receive placebo . The effect evaluate follow : 1 . The effect bone marrow density examine bone scan prior treatment 6 9 month . 2 . The effect bone turnover measure blood- urine sample time . 3 . The effect fat distribution evaluate MRI scan treatment . 4 . The effect bone marrow cell investigate bone marrow sample immediately treatment 5 . The direct effect fat examine biopsy immediately treatment The study hypothesis rosiglitazone treatment decrease bone mineral density increase bone marrow fat content . The causal molecular mechanism investigate bone marrow fat sample</brief_summary>
	<brief_title>The Effect Glitazone Treatment Bone Marrow Bone Marrow Cells</brief_title>
	<detailed_description />
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Postmenopausal woman age 6075 rosiglitazone allergy Osteoporosis Diabetes Hyperthyroidism , untreated hypothyroidism , hyperparathyroidism Treatment bone active drug Low impact fracture Heart disease Kidney failure Liver failure Anaemia Ineligibility MRIscan Cancer within last 5 year</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>BMD</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Bone marrow fat</keyword>
</DOC>